Drug Trial Radar · NCT06799637
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Dec 1, 2023
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Evopoint Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies. The study consists of two parts: a dose escalation part and a dose expansion part.
Conditions
- Advanced Solid Tumors
- Pancreatic Carcinoma
- Ovarian Cancer
- Cervical Cancers
Interventions
XNW28012Drug
Eligible subjects will receive XNW28012 every 3 weeks (Q3W) until intolerant toxicity, progression of disease with no clinical benefit, or withdrawal of informed consent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ph 1: Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability].Time frame: through study completion, an average of 1 year
- Ph 2: To evaluate the antitumor efficacy of XNW28012 at the recommended Part 2 dose.Time frame: through study completion, an average of 1 year
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China · Recruiting
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Recruiting
Affiliated Hospital of Hebei University
Baoding, Hebei, China · Recruiting
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Recruiting
First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The Second Xiangya Hospital Of Central South University
Changsha, Hunan, China · Recruiting
First Affiliated Hospital of Gannan Medical College
Ganzhou, Jiangxi, China · Recruiting
First Affiliated Hospital of Kunming Medical University
Yunnan, Kunming, China · Recruiting
Affiliated Hospital of Binzhou Medical College
Binzhou, Shandong, China · Recruiting
Jinan Central Hospital
Jinan, Shandong, China · Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.